Original Article : High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice
분야
의약학 > 내과학
저자
( Nae Yun Heo ) , ( Young Suk Lim ) , ( Han Chu Lee ) , ( Yung Sang Lee ) , ( Kang Mo Kim ) , ( Kwan Soo Byun ) , ( Kwang Hyub Han ) , ( Kwan Sik Lee ) , ( Seung Woon Paik ) , ( Seung Kew Yoon ) , ( Dong Jin Suh )
발행기관
대한간학회
간행물정보
Clinical and Molecular Hepatology(대한간학회지) 2013년, 제19권 제1호, 60~69페이지(총10페이지)
파일형식
27405559.pdf [무료 PDF 뷰어 다운로드]
  • ※ 본 자료는 참고용 논문으로 수정 및 텍스트 복사가 되지 않습니다.
  • 구매가격
    4,500원
    적립금
    135원 (구매자료 3% 적립)
    이메일 발송  스크랩 하기
    자료 다운로드  네이버 로그인
    영문초록
    Background/Aims: Identifying the impact of a patient`s ethnicity on treatment responses in clinical practice may assist in providing individualized treatment regimens for chronic hepatitis C (CHC). The effectiveness of standard peginterferon plus ribavirin therapy and the need for triple combination therapy with protease inhibitors in Koreans remain matters of debate. These issues were investigated in the present study. Methods: The clinical data of 272 treatment-na?ve Korean CHC patients who were treated in a community-based clinical trial (Clinical Trial group; n=51) and in clinical practice (Cohort group; n=221), were analyzed and compared. All were treated with standard protocols of peginterferon alfa-2a plus ribavirin therapy. Results: For patients with hepatitis C virus (HCV) genotype 1, the sustained virological response (SVR) rates in the Clinical Trial and Cohort groups were 81% (21/26) and 55% (58/106), respectively, by intention-to-treat (ITT) analysis ( P=0.02), and 100% (13/13) and 80% (32/40), respectively, in treatment-adherent patients ( P=0.18). For patients with HCV genotype 2, the SVR rates in these two groups were 96% (24/25) and 88% (101/115), respectively, by ITT analysis ( P=0.31). Adherence and treatment duration were independent predictors of SVR for genotypes 1 and 2, respectively ( P<0.01 for each). Korean patients with CHC achieved high SVR rates with peginterferon alfa-2a plus ribavirin in both the clinical trial and clinical practice settings. Conclusions: Measures to raise adherence to standard therapy in clinical practice may improve the SVR rates in these patients as effectively as adding protease inhibitors, thus obviating the need for the latter. (Clin Mol Hepatol 2013;19:60-69)
    사업자등록번호 220-87-87785 대표.신현웅 주소.서울시 서초구 방배로10길 18, 402호 대표전화.070-8809-9397
    개인정보책임자.박정아 통신판매업신고번호 제2017-서울서초-1765호 이메일 help@reportshop.co.kr
    copyright (c) 2009 happynlife. steel All reserved.